Page 38 - Recursion Pharmaceuticals News Today

Initiated five clinical trials in 2022, including three Phase 2 programs, and provided guidance on the timing of clinical data readoutsDelivered against...

BioPharma

/PRNewswire/ -- The "Batten Disease - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.coms offering. This "Batten Disease -...

/PRNewswire/ -- DelveInsights Clostridium difficile Infection Market Insights report includes a comprehensive understanding of current treatment practices,...

The Clostridium difficile infection market is anticipated to surge owing to the launch of emerging therapies. The potential emerging treatment expected to launch in the forecast period includes

As gene sequencing, machine learning, powerful imaging, sensors, gene and cell therapies make their way out of academic labs into everyday healthcare, our approach to healthcare is changing. For the first time, not only can we pinpoint the molecular and genetic causes of disease, but we also have the technologies to access them. On the back of this, prevention and cures are becoming possible. Can we afford them?

In the underground world of pronatalism, the elite think it's their duty to fill the earth with their kids — and are funding tech to make it happen.

Item 2.02. Results of Operations and Financial Condition. On November 8, 2022, Recursion Pharmaceuticals, Inc. issued a press release announcing its results of operations and financial condition for... | November 8, 2022

Harvard Management Company was established in 1974 and manages Harvard Universitys endowment and financial assets.

Ochre Bio is looking for ways to regenerate poor quality donor livers, to give more people access to better quality organs for transplants.